Zydus Cadila‘s US subsidiary has got the approval from the US health regulator for marketing oseltamivir phosphate capsules that are used in treating Tamiflu.
Cadila Healthcare has said in a BSE filing that “Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the United States Food and Drug Administration (USFDA) for marketing oseltamivir phosphate capsules in strengths of 30 mg, 45 mg, and 75 mg.”
The company, quoting IMS December 2016 sales data said oseltamivir phosphate capsules had sales worth USD 382 million.
